<DOC>
	<DOCNO>NCT01354301</DOCNO>
	<brief_summary>Despite improvement efficacy result current immunosuppressive regimen ( 15 % incidence acute rejection ) , security scheme use show results.The worldwide use regime tacrolimus , mycophenolate prednisone . Despite favorable efficacy result population , use combination associate high incidence viral infection cytomegalovirus , gastrointestinal event , two common cause hospital readmission renal transplantation institution.Given , investigator propose study initiative attends local need : identify best strategy among therapeutic option available maintain result current effectiveness improve safety profile kidney transplant recipients.This protocol prospective , randomize , single center , design compare safety efficacy three immunosuppressive regimen : ( 1 ) single dose antithymocyte globulin , reduce exposure tacrolimus , everolimus start day 2 transplantation prednisone ; ( 2 ) basiliximab , reduce exposure tacrolimus , everolimus start day 2 transplantation prednisone ; ( 3-control group ) basiliximab , reduce exposure tacrolimus , mycophenolate prednisone.Our hypothesis single dose antithymocyte globulin basiliximab induction therapy combination low dos tacrolimus , everolimus prednisone result comparable efficacy observe patient receive tacrolimus / mycophenolate / prednisone , good safety profile . To ensure efficacy , investigator add regime induction monoclonal polyclonal antibody . To improve toxicity associate current scheme , investigator replace use mycophenolate everolimus investigator reduce dose tacrolimus . Patients monitor blood level tacrolimus everolimus ensure adequate exposure immunosuppressive agent .</brief_summary>
	<brief_title>Efficacy Safety Induction Strategies Combined With Low Tacrolimus Exposure Kidney Transplant Recipients Receiving Everolimus Sodium Mycophenolate</brief_title>
	<detailed_description>Primary end-point : The incidence CMV infection disease first year transplantation.Secondary main end-point : incidence treatment failure define composite end-point BCAR , graft loss , death , loss follow . The investigator anticipate enrol 300 patient within 12 month . Only low risk adult candidate first renal transplant live deceased donor consider enrollment . Patients exclude receive immunosuppressive therapy transplantation ; receive investigational medication within past 30 day ; know contraindication administration antithymocyte globulin ; test positive human immunodeficiency virus ( HIV ) ; cancer ( except nonmelanoma skin cancer ) within previous 2 year . Pregnant woman , nurse mother , woman childbearing potential use condoms oral contraceptive exclude . Patients panel reactive antibody ( PRA ) equal 50 % , class I class II , also exclude . Study visit perform pre transplant , day 0 , 1 , 7 , every week month 6 month 12 .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>low risk adult candidate first renal transplant live deceased donor receive immunosuppressive therapy transplantation ; receive investigational medication within past 30 day ; know contraindication administration antithymocyte globulin ; test positive human immunodeficiency virus ( HIV ) ; cancer ( except nonmelanoma skin cancer ) within previous 2 year ; Pregnant woman , nurse mother , woman childbearing potential use condoms oral contraceptive exclude ; Patients panel reactive antibody ( PRA ) equal 50 % , class I class II .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>kidney transplantation</keyword>
	<keyword>thymoglobulin</keyword>
	<keyword>everolimus</keyword>
</DOC>